Expertise in
4
conditions

Dr. Elliot M. Stieglitz

Hematology | Oncology
University Of California At San Francisco
1825 4th St, 
San Francisco, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
4
conditions
University Of California At San Francisco
1825 4th St, 
San Francisco, CA 

Overview

Elliot Stieglitz is a Hematologist and an Oncologist practicing medicine in San Francisco, California.

Dr. Stieglitz is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Leukemia, Acute Lymphoblastic Leukemia (ALL), RASopathies, Acute Myeloid Leukemia (AML), and Splenectomy.

He is actively involved in clinical research, co-authoring 82 peer reviewed articles and participating in 3 clinical trials.

Specialties

Hematology
Oncology

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

University of California at San Francisco
1825 4th St, San Francisco, CA 94143

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2026
Intervention Type: Procedure, Drug
Study Drug: Trametinib
Study Phase: Phase 2
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.
Enrollment Status: Active_not_recruiting
Publish Date: May 29, 2026
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 1
View 2 Less Clinical Trial

82 Total Publications

Ribonucleotide Reductase Inhibition Overcomes FLT3 Inhibitor Resistance in Acute Myeloid Leukemia.
Ribonucleotide Reductase Inhibition Overcomes FLT3 Inhibitor Resistance in Acute Myeloid Leukemia.
Journal: bioRxiv : the preprint server for biology
Published: August 01, 2026
Similar Doctors
Expertise in
12
conditions
Dr. Elliott P. Vichinsky
Hematology | Oncology
Expertise in
12
conditions
Dr. Elliott P. Vichinsky
Hematology | Oncology
Referral may be required

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
 (8.3 miles away)
510-428-3372
Languages Spoken:
English
See accepted insurances

Elliott Vichinsky is a Hematologist and an Oncologist practicing medicine in Oakland, California. Dr. Vichinsky is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Expertise in
13
conditions
Dr. Ashutosh P. Lal
Hematology | Oncology
Expertise in
13
conditions
Dr. Ashutosh P. Lal
Hematology | Oncology
Referral may be required

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
 (8.3 miles away)
510-428-3374
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Offers Telehealth

Ashutosh Lal is a Hematologist and an Oncologist practicing medicine in Oakland, California. Dr. Lal is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Thalassemia, Beta Thalassemia, Congenital Hemolytic Anemia, Hemoglobinopathy, and Splenectomy.

Expertise in
11
conditions
Dr. Mark C. Walters
Hematology | Oncology
Expertise in
11
conditions
Dr. Mark C. Walters
Hematology | Oncology
Referral may be required

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
 (8.3 miles away)
510-428-3374
Languages Spoken:
English
See accepted insurances

Mark Walters is a Hematologist and an Oncologist practicing medicine in Oakland, California. Dr. Walters is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Hemoglobinopathy, Congenital Hemolytic Anemia, Sickle Cell Disease, Hemolytic Anemia, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Elliot M. Stieglitz

How do I make an appointment with Dr. Elliot M. Stieglitz?

You can book an appointment with Dr. Elliot M. Stieglitz by calling their office at 415-476-3831. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Elliot M. Stieglitz a top-rated expert for Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Elliot M. Stieglitz is classified as an Distinguished expert for Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Elliot M. Stieglitz specialize in?

While Dr. Elliot M. Stieglitz is a Hematology, they have specific expertise in Leukemia, Acute Lymphoblastic Leukemia (ALL), and RASopathies. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Elliot M. Stieglitz participate in research or clinical trials?

Yes. Dr. Elliot M. Stieglitz has published 82 articles and abstracts on conditions like Leukemia. You can view a list of Dr. Elliot M. Stieglitz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Elliot M. Stieglitz accept my insurance?

Dr. Elliot M. Stieglitz accepts most major insurance plans, including Anthem BCBS and Blue Shield of California. We recommend calling the office directly at 415-476-3831 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stieglitz's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile